2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Research 2013, 15: r86. PMID: 24060333, PMCID: PMC3978752, DOI: 10.1186/bcr3481.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsCell ProliferationChemoradiotherapy, AdjuvantEstrogensFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedMitosisNeoplasm GradingNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPrognosisReceptors, EstrogenRiskSignal TransductionTamoxifenConceptsNode-negative tumorsLate relapseNeoadjuvant letrozoleEndocrine therapyEarly relapseNegative tumorsBreast cancerEstrogen receptor-positive breast cancerProliferation markersReceptor-positive breast cancerER-positive breast cancerAdjuvant endocrine therapyAffymetrix gene expression profilesExtended endocrine therapyTamoxifen-treated patientsER-positive patientsGenomic grade indexPositive breast cancerRisk of recurrenceRisk of relapseEstrogen receptor activitySmall independent cohortEstrogen-related genesAdjuvant tamoxifenSystemic therapy
2011
S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.
Bianchini G, Pusztai L, Iwamoto T, Kelly C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. DOI: 10.1158/0008-5472.sabcs11-s1-7.Peer-Reviewed Original ResearchDistant relapse ratesPatterns of relapseAromatase inhibitorsLate relapseRelapse rateHigh riskTime cohortsEstrogen receptor-positive casesOncotype DX recurrence scoreAdjuvant clinical trialsEndocrine-sensitive cancersEndocrine-sensitive tumorsLow-proliferation tumorYears of tamoxifenNode-negative tumorsReceptor-positive casesUse of tamoxifenDX recurrence scoreBiomarker groupsEndocrine therapyEndocrine drugsEarly relapseEndocrine resistanceLate recurrenceRisk stratification